Tocqueville Asset Management L.P. cut its position in Nektar Therapeutics (NASDAQ:NKTR) by 0.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 232,402 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Tocqueville Asset Management L.P. owned approximately 0.15% of Nektar Therapeutics worth $4,543,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in NKTR. Flinton Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the period. Meadow Creek Investment Management LLC increased its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 616 shares in the last quarter. LS Investment Advisors LLC increased its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 535 shares in the last quarter. Glen Harbor Capital Management LLC increased its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 784 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 1,464 shares in the last quarter. Institutional investors and hedge funds own 93.02% of the company’s stock.

Nektar Therapeutics (NASDAQ NKTR) opened at 18.67 on Friday. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The company’s 50-day moving average is $20.31 and its 200-day moving average is $18.74. The company’s market cap is $2.92 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. The business had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.36) earnings per share. On average, equities research analysts expect that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Tocqueville Asset Management L.P. Sells 2,000 Shares of Nektar Therapeutics (NKTR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/25/tocqueville-asset-management-l-p-sells-2000-shares-of-nektar-therapeutics-nktr.html.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Nektar Therapeutics in a research note on Friday, August 18th. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a research note on Monday, August 7th. They issued a “buy” rating and a $31.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $26.10.

In other Nektar Therapeutics news, Director Roy A. Whitfield bought 35,000 shares of the stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $17.95 per share, for a total transaction of $628,250.00. Following the completion of the transaction, the director now owns 133,000 shares in the company, valued at approximately $2,387,350. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total transaction of $32,863.32. Following the transaction, the senior vice president now owns 31,102 shares in the company, valued at $600,890.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 237,629 shares of company stock worth $4,820,217. Insiders own 6.10% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.